Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Gains from Investment Securities (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Gains from Investment Securities for 8 consecutive years, with -$443000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Investment Securities fell 110.03% year-over-year to -$443000.0, compared with a TTM value of -$444000.0 through Dec 2024, down 110.05%, and an annual FY2024 reading of $4.1 million, down 8.3% over the prior year.
  • Gains from Investment Securities was -$443000.0 for Q4 2024 at Puma Biotechnology, down from $105646.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.4 million in Q1 2021 and bottomed at -$443000.0 in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $2.1 million, with a median of $640748.0 recorded in 2021.
  • The sharpest move saw Gains from Investment Securities surged 536298.7% in 2020, then tumbled 110.03% in 2024.
  • Year by year, Gains from Investment Securities stood at $65000.0 in 2020, then plummeted by 101.54% to -$1000.0 in 2021, then surged by 58335.3% to $582353.0 in 2022, then skyrocketed by 658.76% to $4.4 million in 2023, then tumbled by 110.03% to -$443000.0 in 2024.
  • Business Quant data shows Gains from Investment Securities for PBYI at -$443000.0 in Q4 2024, $105646.0 in Q3 2024, and $4.4 million in Q4 2023.